Clinical trials in Duesseldorf – page 33

In Düsseldorf, a large share of trials focuses on cancer research and blood cancers, with studies in breast cancer, colorectal cancer, prostate cancer, multiple myeloma, and leukemia. These trials are mainly testing new treatment combinations, improving post-surgery care, and exploring ways to delay or prevent recurrence.

• Breast cancer and triple-negative breast cancer research
• Colorectal cancer, prostate cancer, and other solid tumors
• Multiple myeloma, lymphoma, AML, and MDS
• Testing new therapy strategies and improving treatment outcomes

This field is especially active across the city’s research sites, reflecting a strong interest in both common and hard-to-treat malignancies.

Another important area is skin and connective tissue disease research, including studies on psoriasis, actinic keratosis, androgenetic alopecia, and facial line treatments. These trials are mainly aimed at evaluating new topical or injectable therapies and improving visible symptom control.

• Moderate to severe plaque psoriasis
• Actinic keratosis of the face or scalp
• Androgenetic alopecia in men and women
• Facial line and cosmetic treatment studies

Several of these studies are designed to compare active treatment with control care and help refine everyday dermatologic treatment options.

Trials in digestive system diseases and virus diseases include research on chronic hepatitis D, metabolic dysfunction-associated steatotic liver disease, and advanced cancers involving the pancreas, colon, and bile ducts. The main goal is to improve treatment effectiveness and support better disease control in difficult liver and gastrointestinal conditions.

• Chronic hepatitis D infection
• Metabolic dysfunction-associated steatotic liver disease
• Pancreatic, colon, and cholangiocarcinoma studies
• Testing new therapies and surgery-related strategies

These studies highlight a strong focus on therapies for chronic liver illness and advanced abdominal cancers.

Research in nervous system diseases includes trials for multiple sclerosis and other neurological conditions, with an emphasis on long-term safety and treatment benefit. In Düsseldorf, these studies are helping assess whether newer immune-based approaches can better support patients over time.

• Relapsing multiple sclerosis
• Progressive multiple sclerosis
• Broader nervous system disease research
• Evaluating treatment safety and durability

This area reflects ongoing interest in therapies that may offer steadier disease control with acceptable tolerability.

Pediatric trials cover serious conditions such as high-risk neuroblastoma, acute lymphoblastic leukemia, and respiratory distress in preterm infants. These studies aim to improve survival, reduce complications, and support better long-term outcomes in children and young people.

• High-risk neuroblastoma
• Ph+ and ABL-class B-cell acute lymphoblastic leukemia
• Respiratory distress syndrome in preterm infants
• Testing more effective treatment and prevention approaches

These trials bring together cancer care and neonatal research, showing a wide pediatric research footprint in the city.

Several studies address hemic and lymphatic diseases, especially myelodysplastic syndromes, anemia, and refractory hematologic malignancies. The purpose is to find better ways to restore blood counts, improve transfusion independence, and treat patients whose disease has returned or no longer responds to standard therapy.

• Lower-risk myelodysplastic syndromes
• Anemia linked to marrow disorders
• Relapsed or refractory mantle cell lymphoma
• Evaluating new blood cancer treatments

This research area is particularly important for patients with limited treatment options and persistent blood-related symptoms.

Düsseldorf also hosts trials in hormonal diseases and nutritional and metabolic diseases, including work on hair loss linked to hormonal imbalance and liver-related metabolic disorders. These studies are designed to test treatment effectiveness and improve symptom management in conditions that often affect quality of life.

• Hormone-related hair loss
• Metabolic liver disease
• Treatment studies in endocrine and metabolic care
• Assessing benefit and safety of newer therapies

These trials connect chronic metabolic care with visible, patient-centered outcomes.

The city’s trial portfolio includes immune system disease research and studies linked to virus diseases, especially where immune pathways affect chronic illness or cancer care. Researchers are exploring new treatment options that may improve control of persistent viral infection and immune-driven disease.

• Chronic hepatitis D
• Immune-related treatment strategies
• Conditions involving chronic inflammation and infection
• Evaluating newer immune-targeted therapies

This work shows how immunology and virology often overlap in modern clinical research.

A smaller but important part of the research landscape involves diagnostic techniques and equipment, including studies that assess how well advanced imaging can identify disease and guide care. These trials are focused on improving diagnosis and helping clinicians distinguish between disease subtypes more accurately.

• Prostate cancer imaging and diagnosis
• Evaluating PET-based diagnostic performance
• Improving disease classification
• Supporting earlier and more precise diagnosis

In Düsseldorf, diagnostic research complements the treatment studies by strengthening the tools used to identify and monitor disease.

Trials in respiratory tract diseases include research aimed at improving outcomes for preterm infants with breathing problems early in life. The focus is on prevention and better long-term lung function, with the goal of reducing complications that can affect childhood development.

• Respiratory distress syndrome in premature babies
• Early intervention and prevention strategies
• Long-term lung health
• Supporting better outcomes in neonatal care

This area links specialized newborn care with research designed to improve later respiratory health.

Some trials in Düsseldorf span advanced solid tumors and other difficult-to-treat conditions, reflecting a broad translational research effort. These studies are often designed to test whether new therapies can produce meaningful disease control in patients with limited standard options.

• Advanced solid tumors
• Mixed oncology populations
• Early evaluation of promising therapies
• Exploring anti-tumor activity and safety

This part of the research landscape supports the development of new approaches across multiple cancer types.